Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Observation of tt[over ¯] Production in Pb+Pb Collisions at sqrt[s_{NN}]=5.02 TeV with the ATLAS Detector.

Physical review letters·2025

Same author

Search for Dark Matter Produced in Association with a Dark Higgs Boson in the bb[over ¯] Final State Using pp Collisions at sqrt[s]=13 TeV with the ATLAS Detector.

Physical review letters·2025

Same author

Search for Magnetic Monopole Pair Production in Ultraperipheral Pb+Pb Collisions at sqrt[s_{NN}]=5.36 TeV with the ATLAS Detector at the LHC.

Physical review letters·2025

Same author

Simultaneous Unbinned Differential Cross-Section Measurement of Twenty-Four Z+jets Kinematic Observables with the ATLAS Detector.

Physical review letters·2025

Same author

Disentangling Sources of Momentum Fluctuations in Xe+Xe and Pb+Pb Collisions with the ATLAS Detector.

Physical review letters·2025

Same author

Search for Light Long-Lived Particles in pp Collisions at sqrt[s]=13 TeV Using Displaced Vertices in the ATLAS Inner Detector.

Physical review letters·2024

Search research articles

Related Experiment Video

Updated: May 23, 2026

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

Chelating agents for neurodegenerative diseases.

R J Ward¹, D T Dexter, R R Crichton

¹Universite Catholique de Louvain, 1348 Louvain-la-Neuve, Belgium. wardrobertaj@gmail.com

Current Medicinal Chemistry

|April 12, 2012

Summary

Metal ion imbalance in the brain, particularly copper, iron, and zinc, is linked to neurodegenerative diseases. Chelation therapy offers a potential treatment by removing excess metals, including strategies for brain-penetrating chelators.

More Related Videos

Viability Assays for Cells in Culture

Viability Assays for Cells in Culture

Published on: January 20, 2014

Related Experiment Videos

Last Updated: May 23, 2026

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

Viability Assays for Cells in Culture

Viability Assays for Cells in Culture

Published on: January 20, 2014

Area of Science:

Neuroscience
Biochemistry
Pharmacology

Background:

Metal ion homeostasis (copper, iron, zinc) is crucial for brain function.
Dysregulation and accumulation of these metals are implicated in neurodegenerative diseases.
Chelation therapy is a potential therapeutic strategy for these conditions.

Purpose of the Study:

To review the role of metal ion homeostasis in neurodegeneration.
To discuss the potential of chelation therapy for brain disorders.
To explore strategies for developing blood-brain-barrier-penetrating chelators.

Main Methods:

Literature review of metal ion homeostasis in aging and neurodegenerative diseases.
Analysis of current chelating agents and their limitations.
Discussion of novel chelator development strategies.

Main Results:

Iron, copper, and zinc dyshomeostasis is observed in aging and neurodegenerative conditions like Parkinson's and Alzheimer's disease.
Existing chelators have limitations in crossing the blood-brain-barrier.
New strategies are being developed to enhance chelator brain penetration.

Conclusions:

Chelation therapy holds promise for treating neurodegenerative diseases linked to metal ion dyshomeostasis.
Targeted development of brain-penetrating chelators is essential for effective treatment.
Further research is needed to optimize chelation strategies for specific neurodegenerative conditions.